cookies-img
We use third-party cookies to provide support. By continuing to browse this website, you accept our privacy policy.
close-icon
Kiniksa Pharmaceuticals Ltd
7 own
10 watching
Current Price
$20.59
$0.1
(0.49%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Market Capitalization
Market Capitalization
1,854.64M
52-Week High
52-Week High
28.15000
52-Week Low
52-Week Low
16.56000
Average Volume
Average Volume
0.59M
Dividend Yield
Dividend Yield
--
P/E Ratio
P/E Ratio
--
iconMarket Capitalization1,854.64M
icon52-Week High28.15000
icon52-Week Low16.56000
iconAverage Volume0.59M
iconDividend Yield--
iconP/E Ratio--
What does the Kiniksa Pharmaceuticals Ltd do?
Kiniksa Pharmaceuticals, Ltd. is a biopharmaceutical company. The Company is focused on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases. Its portfolio of immune-modulating assets, ARCALYST (rilonacept), KPL-404 and mavrilimumab, are based on strong biologic rationale or validated mechanisms, target a spectrum of underserved cardiovascular and autoimmune conditions, and offer the potential for differentiation. The Company’s ARCALYST is interleukin-1alpha (IL-1α), and interleukin-1beta (IL-1β), cytokine trap for the treatment of recurrent pericarditis and reduction in risk of recurrence in adults and children. Its KPL-404 is an investigational monoclonal antibody inhibitor of CD40-CD154 interaction. The Company’s Mavrilimumab is an investigational monoclonal antibody inhibitor targeting granulocyte-macrophage colony stimulating factor receptor alpha (GM-CSFRα).
Read More
How much money does Kiniksa Pharmaceuticals Ltd make?
News & Events about Kiniksa Pharmaceuticals Ltd.
Globe Newswire
1 year ago
ARCALYST (rilonacept) Q4 2022 and full-year 2022 net product revenue of $39.9 million and $122.5 million, respectively (unaudited) 2 of 3 cohorts enrolled in KPL-404 Phase 2 trial in rheumatoid arthritis; data expected in 1H 2024 Cash reserves expected to fund operations into at least 2025 HAMILTON...
Market News Video
2years ago
In trading on Tuesday, shares of Kiniksa Pharmaceuticals Ltd (KNSA) crossed below their 200 day moving average of 10.67, changing hands as low as 10.24 per share. Kiniksa Pharmaceuticals Ltd shares are currently trading down about 5.2% on the day...
Globe Newswire
2years ago
HAMILTON, Bermuda, Sept. 12, 2022 (GLOBE NEWSWIRE) -- Kiniksa Pharmaceuticals, Ltd. (Nasdaq: KNSA) (Kiniksa), a biopharmaceutical company with a portfolio of assets designed to modulate immunological pathways across a spectrum of diseases, today announced the closing of the global license agreement ...
Frequently Asked Questions
Frequently Asked Questions
What is Kiniksa Pharmaceuticals Ltd share price today?
plus_minus_icon
Can Indians buy Kiniksa Pharmaceuticals Ltd shares?
plus_minus_icon
How can I buy Kiniksa Pharmaceuticals Ltd shares from India?
plus_minus_icon
Can Fractional shares of Kiniksa Pharmaceuticals Ltd be purchased?
plus_minus_icon
What are the documents required to start investing in Kiniksa Pharmaceuticals Ltd stocks?
plus_minus_icon
What is today’s traded volume of Kiniksa Pharmaceuticals Ltd?
plus_minus_icon
What is today’s market capitalisation of Kiniksa Pharmaceuticals Ltd?
plus_minus_icon
What is the 52-Week High and Low Range of Kiniksa Pharmaceuticals Ltd?
plus_minus_icon
What percentage is Kiniksa Pharmaceuticals Ltd down from its 52-Week High?
plus_minus_icon
What percentage is Kiniksa Pharmaceuticals Ltd up from its 52-Week Low?
plus_minus_icon
Current Price
$20.59
$0.1
(0.49%)
arrow-icon
1 Week Returns
3 Months Returns
1 Year Returns

Get Started with as little as $1.00

Related Stocks
SCHOLAR ROCK HOLDING CORP
SCHOLAR ROCK HOLDING CORP
$44.78
$2.69 (6.39 %)
PRAXIS PRECISION MEDICINES I
PRAXIS PRECISION MEDICINES I
$76.52
$3.68 (5.05 %)
CABALETTA BIO INC
CABALETTA BIO INC
$2.38
$0.07 (3.03 %)
Applied Therapeutics Inc
Applied Therapeutics Inc
$0.88
$-0.14 (-13.73 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.
Related Stocks
SCHOLAR ROCK HOLDING CORP
SCHOLAR ROCK HOLDING CORP
$44.78
$2.69 (6.39 %)
PRAXIS PRECISION MEDICINES I
PRAXIS PRECISION MEDICINES I
$76.52
$3.68 (5.05 %)
CABALETTA BIO INC
CABALETTA BIO INC
$2.38
$0.07 (3.03 %)
Applied Therapeutics Inc
Applied Therapeutics Inc
$0.88
$-0.14 (-13.73 %)
Sign up and dive into a whole new world of investing.
Join over 500,000 who have signed up and are using Stockal successfully already.

              Borderless Softtech Pvt Ltd ("BSPL") licenses and offers the Stockal Platform to subscribers and users who are based in India and wish to make global transactions. Such subscribers and users may be offered annual or monthly subscription plans by BSPL and in such cases, BSPL acts as their service provider.

              Borderless Investing Inc., (“Borderless Investing”), the owner of the Stockal Platform, is not a broker-dealer nor an investment advisor and through its affiliate stockbroker Stockal Securities Pvt. Ltd., (SEBI INZ000301236), acting as the introducing entity has entered into a clearing agreement with DriveWealth LLC., to offer U.S. equities on the Stockal Platform. The Stockal Platform enables investments in a diverse set of global assets from a single account from anywhere in the world. As such, Borderless Investing makes no warranties or representations, express or implied, on products and services offered through its website/platform. It accepts no liability for any damages or losses, however, caused in connection with the use of related services.

              All investments involve risk and returns will fluctuate, are subject to market volatility and may cause losses. The material on this website/platform is provided solely for informational and educational purposes and shall not in any manner be considered a recommendation or endorsement of any strategy or investment, nor an offer to sell or a solicitation of an offer to buy securities, products or services nor advice. Borderless Investing makes no guarantee as to the currency, accuracy, or quality of information published and/or archived on this website/platform, nor will Borderless Investing accept any responsibility for other organizations, businesses, and private persons that provide information on this website/platform. All information on this website/platform regarding products and services provided by Borderless Investing is subject to change without notice. Reasonable efforts are taken to ensure the accuracy and integrity of all information provided here, but Borderless Investing is not responsible for misprints, out of date information, or errors. Any investment decision and/or strategy that investors make or employ, whether or not such decision or strategy derives from or relies upon material accessed or provided through this website/platform, is undertaken at the investor’s sole discretion and risk. Before making any investment decisions, investors should consult additional sources of information and/or their legal or tax advisor. PLEASE READ THIS FULL DISCLOSURE CAREFULLY BEFORE USING THIS SERVICE. BY USING THE SERVICE OR CLICKING AGREE YOU ARE AGREEING TO BE BOUND BY THESE DISCLOSURES AND ALL TERMS AND CONDITIONS ON THIS WEBSITE/PLATFORM.

              *DriveWealth LLC., a member of the Securities Investor Protection Corporation (SIPC), will serve as the custodian for your securities account. In the event that DriveWealth LLC., fails and is placed in liquidation under the Securities Investor Protection Act, securities in your brokerage account may be protected up to $500,000. For details, please see www.sipc.org.

              All brands and logos used on this website are the property of their respective owners.

              Get Started with as little as $1.00